Cancer vaccines: on the threshold of success

Bibliography

• Shibuya K, Mathers C, Boschi-Pinto C, et al. Global and regional estimates of cancer mortality and incidence by site. II. Results for the global burden of disease 2000. BMC Cancer 2002;2:1-26
   PubMedGoogle Scholar
• Salminen E, Izewska J, Andreo P. IAEA's role in the global management of cancer: focus on upgrading radiotherapy services. Acta Oncol 2005;44:816-24
   PubMed Web of Science ®Google Scholar
• Kanavos P. The rising burden of cancer in the developing world. Ann Oncol 2006;17:viii15-23
   PubMed Web of Science ®Google Scholar
• Jones S. Cancer in the developing world: a call to action. BMJ 1999;319:505-8
   PubMed Web of Science ®Google Scholar
• Rastogi T, Hildesheim A, Sinha R. Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer 2004;4:909-17
   PubMed Web of Science ®Google Scholar
• Ferlay J, Bray F, Pisani P, Parkin D. GLOBOCAN 2002: cancer incidence, mortality, and prevalence worldwide. IARC CancerBase No. 5, version 2.0; 2004. Available from: http://www.dep.iarc.fr/globocan/database.htm
   Google Scholar
• Coley W. The treatment of malignant tumors by repeated inoculations of Erysipelas: with a report of ten original cases. Am J Med Sci 1893;105:487-511
   Google Scholar
• Germain R. The biochemistry and cell biology of antigen presentation by MHC class I and class II molecules. Implications for development of combination vaccines. Ann NY Acad Sci 1995;754:114-25
   PubMed Web of Science ®Google Scholar
• Huang A, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5
   PubMed Web of Science ®Google Scholar
• Boon T, Cerottini J, Van Den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Ann Rev Immunol 1994;53:337-65
   Google Scholar
• Jenkins M, Schwartz R. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987;165:302-19
   PubMed Web of Science ®Google Scholar
• Gilboa E. The makings of a tumor rejection antigen. Immunity 1999;11:263-70
   PubMed Web of Science ®Google Scholar
• Reilly R, Machiels J, Emens L, et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 2001;61:880-3
   PubMed Web of Science ®Google Scholar
• Reilly R, Emens L, Jaffee E. Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer? Curr Opin Investig Drugs 2001;2:133-5
   PubMedGoogle Scholar
• Greten T, Jaffee E. Cancer vaccines. J Clin Oncol 1999;17:1047-60
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43
   PubMed Web of Science ®Google Scholar
• Giles F, Cortes J, Kantarjian H. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Curr Mol Med 2005;5:615-23
   PubMed Web of Science ®Google Scholar
• Emens L. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 2005;12:243-53
   PubMedGoogle Scholar
• Nahta R, Yu D, Hung M, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-80
   PubMedGoogle Scholar
• Weisberg E, Manley P, Cowan-Jacob S, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345-56
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. FDA briefing information on HPV vaccine. Rockville, MD: Vaccines and Related Biological Products Advisory Committee; 2006
   Google Scholar
• Villa L, Costa R, Petta C, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8
   PubMed Web of Science ®Google Scholar
• Siddiqui M, Perry C. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 2006;66:1263-71
   PubMed Web of Science ®Google Scholar
• Parkin D. The global burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44
   PubMed Web of Science ®Google Scholar
• Chan J, Berek J. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007;25:2975-82
   PubMed Web of Science ®Google Scholar
• Liau L, Prins R, Kiertscher S, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515-25
   PubMed Web of Science ®Google Scholar
• Purcell A, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007;6:404-14
   PubMed Web of Science ®Google Scholar
• Greenland J, Letvin N. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007;25:3731-41
   PubMed Web of Science ®Google Scholar
• Osada T, Woo C, Clay T, et al. Dendritic cell-based immunotherapy. Int Rev Immunol 2006;25:377-413
   PubMed Web of Science ®Google Scholar
• Liu Y, Kanzler H, Soumelis V, Gilliet M. Dendric cell lineage, plasticity, and cross-regulation. Nat Immunol 2001;2:585-9
   PubMed Web of Science ®Google Scholar
• Moser M, Murphy K. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000;1:199-205
   PubMed Web of Science ®Google Scholar
• Schnurr M, Chen Q, Shin A, et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005;105:2465-72
   PubMed Web of Science ®Google Scholar
• Brown R, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001;98:2992-8
   PubMed Web of Science ®Google Scholar
• Satthaporn S, Robins A, Vassanasiri W, et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 2004;53:510-8
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Klein J, Paliard X, et al. Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells. J Immunother 2000;23:48-58
   PubMed Web of Science ®Google Scholar
• Mortarini R, Anichini A, Di Nicola M, et al. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 1997;57:5534-41
   PubMed Web of Science ®Google Scholar
• Copier J, Dalgleish A. Overview of tumor cell-based vaccines. Int J Immunol 2006;25:297-319
   Google Scholar
• Bakker AB, Schreurs MW, De Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-9
   PubMed Web of Science ®Google Scholar
• Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95
   PubMed Web of Science ®Google Scholar
• Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42
   PubMed Web of Science ®Google Scholar
• Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-9
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Delgado C, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9
   PubMed Web of Science ®Google Scholar
• Van Der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188:51-64
   PubMed Web of Science ®Google Scholar
• Huang A, Bruce A, Pardoll D, Levitsky H. In vivo cross-priming of MHC class I-restricted antigens requires TAP transporter. Immunity 1996;4:349-55
   PubMed Web of Science ®Google Scholar
• Thomas A, Santarsiero L, Lutz E, et al. Mesothelin-specific CD8+ T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297-306
   PubMed Web of Science ®Google Scholar
• Pandha H, Eaton J, Greenhalgh R, et al. Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy. Cancer Gene Ther 2005;12:572-8
   PubMed Web of Science ®Google Scholar
• Schirrmacher B. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 2005;54:587-98
   PubMed Web of Science ®Google Scholar
• Hege K, Jooss K, Pardoll D. GM-CSF gene-modified cancer cell immunotherapies: of mice and men. Int J Immunol 2006;25:321-52
   Google Scholar
• Binder R. Heat shock protein vaccines: from bench to bedside. Int J Immunol 2006;25:353-75
   Google Scholar
• Srivastava P, Udono H, Blachere N, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994;39:93-8
   PubMed Web of Science ®Google Scholar
• Basu S, Binder R, Ramalingam T, Srivastava P. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001;14:303-13
   PubMed Web of Science ®Google Scholar
• Binder R, Han D, Srivastava P. CD91: a receptor for heat shock protein gp96. Nat Immunol 2000;1:151-5
   PubMed Web of Science ®Google Scholar
• Mignot G, Roux S, Thery C, et al. Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med 2006;10:376-88
   PubMed Web of Science ®Google Scholar
• Segura E, Nicco C, Lombard B, et al. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T cell priming. Blood 2005;106:216-23
   PubMed Web of Science ®Google Scholar
• Liu C, Yu S, Zinn K, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 2006;176:1375-85
   PubMed Web of Science ®Google Scholar
• Dai S, Wan T, Wang B, et al. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin Cancer Res 2005;11:7554-63
   PubMed Web of Science ®Google Scholar
• Kirkwood J, Ibrahim J, Sosman J, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB – III melanoma: results of Intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80
   PubMed Web of Science ®Google Scholar
• Miles D, Papazisis K. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer 2003;3(Suppl 4):S134-8
   PubMed Web of Science ®Google Scholar
• Mayordomo J, Tres A, Miles D, et al. Long-term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STn-KLH vaccine with KLH control in stage IV breast cancer following first line chemotherapy [abstract]. Proc Am Soc Clin Oncol 2004;23:188
   Google Scholar
• Ibrahim N, Murray J, Parker J, et al. Humoral immune responses to naturally occurring STn in metastatic breast cancer patients (MBC pts) treated with STn-KLH vaccine [abstract]. Proc Am Soc Clin Oncol 2004;23:174
   Google Scholar
• Small E, Schellhammer P, Higano C, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asympomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-70
   PubMed Web of Science ®Google Scholar
• Hsueh E, Essner R, Foshag L, et al. Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma. Ann Surg Oncol 2002;9:486-92
   PubMed Web of Science ®Google Scholar
• Hsueh E, Gupta R, Qi K, Morton D. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998;16:2913-20
   PubMed Web of Science ®Google Scholar
• Sondak V, Liu P, Tuthill R, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058-66
   PubMed Web of Science ®Google Scholar
• Sosman J, Unger J, Liu P, et al. Adjuvant immunotherapy of resected, internediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002;20:2067-75
   PubMed Web of Science ®Google Scholar
• Mitchell M, Abrams J, Thompson J, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alpha-2B compared with high-dose interferon alpha-2B for resected stage III cutaneous melanoma. J Clin Oncol 2007;25:2085-87
   Google Scholar
• Harris J, Ryan L, Hoover H, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000;18:148-57
   PubMed Web of Science ®Google Scholar
• Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal cell carcinoma after radical nephrectomy: phase III, randomized controlled trial. Lancet 2004;363:594-9
   PubMed Web of Science ®Google Scholar
• Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007;30:1-15
   PubMed Web of Science ®Google Scholar
• Emens L, Machiels J, Reilly R, Jaffee E. Chemotherapy: friend or foe to cancer vaccines? Curr Opin Mol Ther 2001;3:77-84
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8:59-73
   PubMed Web of Science ®Google Scholar
• Ercolini A, Ladle B, Manning E, et al. Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. J Exp Med 2005;201:1591-602
   PubMed Web of Science ®Google Scholar
• Machiels J, Reilly R, Emens L, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001;61:3689-97
   PubMed Web of Science ®Google Scholar
• Bracci L, Moschella F, Sestili P, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007;13:644-53
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61
   PubMed Web of Science ®Google Scholar
• Emens L, Jaffee E. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005;65:8059-64
   PubMed Web of Science ®Google Scholar
• Hudis C. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51
   PubMed Web of Science ®Google Scholar
• Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N Engl J Med 2005;353:1673-84
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber R, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer: a randomized controlled trial. Lancet 2007;369:29-36
   PubMed Web of Science ®Google Scholar
• Emens L, Reilly R, Jaffee E. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer 2005;12:1-17
   PubMed Web of Science ®Google Scholar
• Wolpoe M, Lutz E, Ercolini A, et al. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol 2003;171:2161-9
   PubMed Web of Science ®Google Scholar
• Clynes R, Towers T, Presta L, Ravetch J. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6
   PubMed Web of Science ®Google Scholar
• Selenko N, Maidic O, Draxier S, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001;15:1619-26
   PubMed Web of Science ®Google Scholar
• Vega M, Herta-Yepaz S, Garban H, et al. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004;23:3530-40
   PubMed Web of Science ®Google Scholar
• Inoue S, Leitner W, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res 2006;66:7741-7
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5:2963-70
   PubMed Web of Science ®Google Scholar
• Pardoll D. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227-38
   PubMed Web of Science ®Google Scholar
• Diehl L, Den Boer A, Schoenberger S, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999;5:774-9
   PubMed Web of Science ®Google Scholar
• Sotomayor E, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5:780-7
   PubMed Web of Science ®Google Scholar
• Vonderheide R, Flaherty K, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007;25:876-83
   PubMed Web of Science ®Google Scholar
• Sugamura K, Ishii N, Weinberg A. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004;4:420-31
   PubMed Web of Science ®Google Scholar
• Murata S, Ladle B, Kim P, et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol 2006;176:974-83
   PubMed Web of Science ®Google Scholar
• Hurwitz A, Yu T, Leach D, Allison J. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 1998;18:10067-71
   Google Scholar
• Van Elsas A, Hurwitz A, Allison J. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190:355-66
   PubMed Web of Science ®Google Scholar
• Quezada S, Peggs K, Curran M, Allison J. CTLA-4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935-45
   PubMed Web of Science ®Google Scholar
• Attia P, Phan G, Maker A, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53
   PubMed Web of Science ®Google Scholar
• Hodi F, Mihm M, Soiffer R, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100:4712-7
   PubMed Web of Science ®Google Scholar
• Maker A, Phan G, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin-2: a phase I/II study. Ann Surg Oncol 2005;12:1005-16
   PubMed Web of Science ®Google Scholar
• Beck K, Blansfield J, Tran K, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-9
   PubMed Web of Science ®Google Scholar
• Ribas A, Camacho L, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen-4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77
   PubMed Web of Science ®Google Scholar
• Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte-antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741-50
   PubMed Web of Science ®Google Scholar
• Khoury Sj, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004;20:529-38
   PubMed Web of Science ®Google Scholar
• Freeman Gj, Long Aj, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34
   PubMed Web of Science ®Google Scholar
• Sica Gl, Choi Ih, Zhu G, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003;18:849-61
   PubMed Web of Science ®Google Scholar
• Bronte v, Serafini p, Mazzoni A, et al. L-Arginine metabolish in meyloid cells controls T-lymphocyte functions. Trends Immunol 2003;24:301-5
   Web of Science ®Google Scholar
• Mellor Al, Munn DH. Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003;170:5809-13
   PubMed Web of Science ®Google Scholar
• Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by STAT3-signaling in tumor cells. Nat Med 2004;10:48-54
   PubMed Web of Science ®Google Scholar
• Munn Dh, Mellor Al. IDO and tolerance to tumors. Trends Mol Med 2004;10:15-8
   PubMed Web of Science ®Google Scholar
• Ferrone S, Finerty JF, Jaffee EM, Nabel GJ. How much longer will tumor cells fool the immune system? Immunol Today 2000;21:70-2
   PubMedGoogle Scholar
• Schmitz F, Heit A. Protective cancer immunotherapy: what can the immune system contribute? Expert Opin Biol Ther 2008;8:31-43
   PubMed Web of Science ®Google Scholar